Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
40.35
+0.02 (0.05%)
Jun 27, 2025, 4:00 PM - Market closed
Tarsus Pharmaceuticals Employees
Tarsus Pharmaceuticals had 323 employees as of December 31, 2024. The number of employees increased by 79 or 32.38% compared to the previous year.
Employees
323
Change (1Y)
79
Growth (1Y)
32.38%
Revenue / Employee
$723,449
Profits / Employee
-$324,901
Market Cap
1.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 323 | 79 | 32.38% |
| Dec 31, 2023 | 244 | 157 | 180.46% |
| Dec 31, 2022 | 87 | 41 | 89.13% |
| Dec 31, 2021 | 46 | 26 | 130.00% |
| Dec 31, 2020 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TARS News
- 4 weeks ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off - Seeking Alpha
- 7 weeks ago - Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown - PRNewsWire
- 2 months ago - Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements - GlobeNewsWire
- 2 months ago - Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - GlobeNewsWire
- 2 months ago - Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting - GlobeNewsWire
- 3 months ago - Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewsWire